SOURCE: NuGene International, Inc.

NuGene International, Inc.

June 22, 2015 07:01 ET

Independent Clinical Study Concludes NuGene Serum Activates Multiple Anti-Aging Genes

IRVINE, CA--(Marketwired - Jun 22, 2015) - NuGene International, Inc. ("NuGene") (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, announced the conclusions of an independent clinical study. The results of the Company-financed research studied the effect of NuGene's proprietary serum's formulation on the human body's ability to repair and regenerate its skin. The study was conducted by Genemarkers LLC ("GM"), an independent clinical laboratory equipped to analyze gene expression in the human body. The study aimed to understand: 1) if NuGene serum exhibited any cytotoxicity; and 2) how NuGene serum influences gene expression in the skin. 

GM discovered statistically significant results of NuGene serum versus a control after a 24 hour period showing:

  • increased anti-oxidant detoxification and inflammatory response;
  • increased signal related to extracellular matrix remodeling and structural integrity;
  • increased activity related to cell proliferation and renewal;
  • decreased pigmentation;
  • decreased barrier cornification; and
  • decreased extracellular matrix components involved in cell death and tissue imbalance.

The gene expression analysis was performed by harvesting the RNA from skin tissue samples and utilizing quantitative polymerase chain reaction (qPCR). Tissue cytotoxicity was measured by lactate dehydrogenase (LDH) assay. 

"We are very excited about these significant results which indicate a more than double fold increase in multiple skin remodeling genes using our proprietary serum," noted Dr. Sanjay Dhar, NuGene's Director of Research and Development. "These results provide essential information and important insight for future biopharmaceutical product development."

About NuGene International, Inc.
NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments." The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications and inventions. NuGene's goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 10-Q filed with the Commission on May 15, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

Contact Information

  • Investor/ Media Relations:
    Jay Goth
    951.704.6792